Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMUR2 | Q9GZQ4 | 5/20 | 0.57 |
| ▸ | NMUR1 | Q9HB89 | 5/20 | 0.57 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.56 |
| ▸ | RAMP3 | O60896 | 1/20 | 0.54 |
| ▸ | CALCR | P30988 | 1/20 | 0.54 |
| ▸ | TFPI | P10646 | 4/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.53 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.52 |
| ▸ | NPY1R | P25929 | 3/20 | 0.52 |
| ▸ | NPY4R | P50391 | 3/20 | 0.52 |
| ▸ | NPY2R | P49146 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26454802 | 0.96 | EPHA2 (0.59) | NMUR2NMUR1EPHA2RAMP3CALCR | |
| SCHEMBL26454604 | 0.94 | NMUR2 (0.60) | NMUR2NMUR1RAMP3CALCRTFPI | |
| SCHEMBL26454355 | 0.91 | NMUR2 (0.58) | NMUR2NMUR1RAMP3CALCRTFPI | |
| SCHEMBL26454697 | 0.91 | TFPI (0.63) | NMUR2NMUR1RAMP3CALCRTFPI | |
| SCHEMBL17722477 | 0.91 | TFPI (0.63) | NMUR2NMUR1EPHA2RAMP3CALCR | |
| SCHEMBL17722497 | 0.91 | TFPI (0.61) | NMUR2NMUR1EPHA2TFPIOPRM1 | |
| SCHEMBL13086158 | 0.90 | NMUR2 (0.64) | NMUR2NMUR1EPHA2TFPIOPRM1 | |
| SCHEMBL26454508 | 0.90 | TFPI (0.63) | NMUR2NMUR1EPHA2TFPINPY5R | |
| SCHEMBL17722478 | 0.89 | TFPI (0.64) | NMUR2NMUR1EPHA2TFPIOPRM1 | |
| SCHEMBL26454452 | 0.88 | TFPI (0.61) | NMUR2NMUR1RAMP3CALCRTFPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230133885-A1 | NEW SYNTHETIC METHODS USING NATIVE CHEMICAL LIGATION IN FLOW | THE UNIVERSITY OF SYDNEY (AU) | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133885-A1 | NEW SYNTHETIC METHODS USING NATIVE CHEMICAL LIGATION IN FLOW | SCLY, SRM, SELENOI | NMUR2 2350/4885NMUR1 2854/4885EPHA2 2192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.